Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023

October 2017 •
124 pages •
Report ID: 5165081 •
Format: PDF

Summary
Table of contents
Search Inside

Hospital Artificial Intelligence for Immunotherapy drives sales of analytics systems.
Automated cancer immunotherapies from IBM Watson are implemented with artificial intelligence that looks at patient samples to detect the genetic characteristics of the cancer and isolate the immune particularities of the patient. Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans. The analysis of patient records, looking for effectiveness of particular treatments is more work than a human can do, the quantity of data is too high, so the artificial intelligence is being used to do that.

Personalized medicine is driving this market opportunity.
Systems are making a significant difference in saving lives.

Memorial Sloan Kettering physician-scientists are among leaders in the field developing groundbreaking immune therapies that are helping to treat several forms of advanced cancer that were previously untreatable. These scientists have played a lead role in developing and testing the immunotherapy drugs known as checkpoint inhibitors that “release the brakes” on the immune system.

Hospital care management can leverage artificial intelligence. Artificial intelligence is useful for providing highly tailored insights about individual patients for the purpose of personalizing immunotherapy care delivery. Artificial intelligence is useful for helping providers effectively address healthcare delivery because it details genetic specificity regarding individual patients.

The intersection of healthcare and artificial intelligence represents a market opportunity. New strategies are being developed by companies to bring A.I. to healthcare. The business challenges around those efforts are being addressed collectively in partnerships and in forums to bring the technology into the market. Artificial intelligence has an impact on patients, doctors, hospitals, clinical facilities, and the healthcare industry overall.

The ability of an intelligent system to learn from data without upfront human intervention brings significant change to the healthcare delivery system. It relies on the use of unsupervised and semi-supervised machine learning techniques. Segmentation, dimensionality reduction, anomaly detection and pattern recognition are replacing supervised manual techniques for diagnosis and care delivery.

According to Susan Eustis, lead author of the team that wrote the study, “Immunotherapy at Memorial Sloan Kettering (MSK) has been making enormous progress in the treatment of cancer. At Memorial Sloan Kettering, immunotherapy is one of the most promising ways to treat, cure, and ultimately prevent cancer. Immunotherapy at MSK has evolved new immune-based treatments for cancer. Researchers have been at the epicenter of new discoveries in the field, and their work is bringing exciting new treatment options to people with cancer.”

Artificial Intelligence for Hospital Cancer Immunotherapy Market Forecasts
Cancer immunotherapy hospital artificial intelligence market system shipments at $7.4 billion in 2023 are forecast to reach $49.4 billion dollars, worldwide by 2023. These artificial intelligence systems represent a very specialized type of care delivery. Steady growth is anticipated because the severely ill patients with advanced cancer disease can be treated successfully with immunotherapy.

Companies Profiled Market Leaders
General Electric
IBM

Market Participants
Alphabet / Google
GlaxoSmithKline (GSK)
Merck
Prognos
Quest Diagnostics
Safeguard Scientifics
Zebra

Companies Mentioned
Drug discovery artificial intelligence
Exscientia
Berg
Numerate
twoXAR
Atomwise
BenevolentAI.

Veronica helps you find the right report:

+1 718 514 2762
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager